Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 7/20 | 0.66 |
| ▸ | NTSR2 | O95665 | 5/20 | 0.66 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.66 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | F13A1 | P00488 | 2/20 | 0.49 |
| ▸ | TGM2 | P21980 | 2/20 | 0.49 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.48 |
| ▸ | DPP3 | Q9NY33 | 4/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350785 | 0.89 | NTSR1 (0.69) | NTSR1NTSR2SORT1CXCR4TACR1 | |
| SCHEMBL29497199 | 0.82 | NTSR1 (0.79) | NTSR1NTSR2SORT1TACR1OPRM1 | |
| SCHEMBL15080711 | 0.81 | NTSR2 (0.58) | NTSR1NTSR2SORT1CAPN1CTSB | |
| SCHEMBL29733691 | 0.81 | NTSR2 (0.63) | NTSR1NTSR2SORT1CAPN1CTSB | |
| SCHEMBL30007955 | 0.79 | NTSR2 (0.65) | NTSR1NTSR2SORT1KISS1RDPP3 | |
| SCHEMBL12524037 | 0.79 | NTSR1 (0.65) | NTSR1NTSR2SORT1CAPN1CTSB | |
| SCHEMBL31507728 | 0.79 | NTSR2 (0.68) | NTSR1NTSR2SORT1CAPN1CTSB | |
| SCHEMBL30921660 | 0.78 | DPP3 (0.64) | NTSR1NTSR2SORT1CAPN1CTSB | |
| SCHEMBL30140869 | 0.78 | F13A1 (0.64) | NTSR1NTSR2SORT1CAPN1CTSB | |
| SCHEMBL30974182 | 0.78 | NTSR2 (0.70) | NTSR1NTSR2SORT1CAPN1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083820-A1 | METHOD FOR AMELIORATING AUTISM SYMPTOMS BY PHARMACOLOGICAL ACTIVATION OF THE NEUROTENSIN RECEPTOR 1 (NTSR1) | NEW YORK INSTITUTE OF TECHNOLOGY (US) | 2026-03-26 | — | — | US | disclosed |
| US-12453757-B2 | Method for ameliorating autism symptoms by pharmacological activation of the neurotensin receptor 1 (NTSR1) | NEW YORK INSTITUTE OF TECHNOLOGY (US) | 2025-10-28 | — | — | US | disclosed |
| US-12358948-B2 | Neurotensinergic agonists and methods of using same preventing or treating pain | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2025-07-15 | — | — | US | disclosed |
| US-20240398806-A1 | Compositions For and Methods of Treating and/or Preventing Pain | Sanford Burnham Prebys Medical Discovery Inst. | 2024-12-05 | — | — | US | disclosed |
| US-20240181012-A1 | METHOD FOR AMELIORATING AUTISM SYMPTOMS BY PHARMACOLOGICAL ACTIVATION OF THE NEUROTENSIN RECEPTOR 1 (NTSR1) | NEW YORK INSTITUTE OF TECHNOLOGY | 2024-06-06 | — | — | US | disclosed |
| US-11591366-B2 | Macrocyclic compounds and methods of preventing or treating pain | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2023-02-28 | — | — | US | disclosed |
| WO-2022241186-A1 | COMPOSITIONS FOR AND METHODS OF TREATING AND/OR PREVENTING PAIN | DUKE UNIVERSITY (US) | 2022-11-17 | — | — | WO | disclosed |
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083820-A1 | METHOD FOR AMELIORATING AUTISM SYMPTOMS BY PHARMACOLOGICAL ACTIVATION OF THE NEUROTENSIN RECEPTOR 1 (NTSR1) | NTSR1, NTSR2, NPSR1 | NTSR1 1/4885NTSR2 2/4885SORT1 531/4885 |
| US-12453757-B2 | Method for ameliorating autism symptoms by pharmacological activation of the neurotensin receptor 1 (NTSR1) | NTSR1, NTSR2, NPSR1 | NTSR1 1/4885NTSR2 2/4885SORT1 393/4885 |
| US-20240181012-A1 | METHOD FOR AMELIORATING AUTISM SYMPTOMS BY PHARMACOLOGICAL ACTIVATION OF THE NEUROTENSIN RECEPTOR 1 (NTSR1) | NTSR1, NTSR2, NPSR1 | NTSR1 1/4885NTSR2 2/4885SORT1 393/4885 |
| US-11591366-B2 | Macrocyclic compounds and methods of preventing or treating pain | COX15, ACHE, TRPV1 | NTSR1 463/4885NTSR2 200/4885SORT1 4512/4885 |
| US-20240398806-A1 | Compositions For and Methods of Treating and/or Preventing Pain | ARRB1, OPRL1, NPSR1 | NTSR1 4/4885NTSR2 6/4885SORT1 1044/4885 |
| US-12358948-B2 | Neurotensinergic agonists and methods of using same preventing or treating pain | VIP, NTSR2, VIPR2 | NTSR1 5/4885NTSR2 2/4885SORT1 3892/4885 |
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | VIP, NTSR2, VIPR2 | NTSR1 5/4885NTSR2 2/4885SORT1 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.